The synthesis of a radioligand with high potency and selectivity for CCKB/ gastrin receptors
暂无分享,去创建一个
[1] J. G. Vinter,et al. Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons. , 1996, Journal of medicinal chemistry.
[2] C. Low,et al. Improving the affinity and selectivity of a nonpeptide series of cholecystokinin-B/gastrin receptor antagonists based on the dibenzobicyclo[2.2.2]octane skeleton. , 1995, Journal of medicinal chemistry.
[3] M. Bodkin,et al. A new class of non-peptidic cholecystokinin-B/gastrin receptor antagonists based on dibenzobicyclo[2.2.2]octane. , 1994, Journal of medicinal chemistry.
[4] F. Halter,et al. Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. , 1994, Gut.
[5] B. E. Evans,et al. Development of 1,4-benzodiazepine cholecystokinin type B antagonists. , 1993, Journal of medicinal chemistry.
[6] Thomas Kolter,et al. Peptidomimetics for Receptor Ligands—Discovery, Development, and Medical Perspectives , 1993 .
[7] M. Bock,et al. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand. , 1989, Molecular pharmacology.
[8] F. Makovec,et al. Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives. , 1992, Journal of medicinal chemistry.